Physician profile
Gary A James
NPI 1255317178
$5,914.53
in general payments reported to CMS, 2019-2025
42 companies · $569 in 2025
The $569 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $939 · 2020: $889 · 2021: $1,316 · 2022: $1,099 · 2023: $635 · 2024: $468 · 2025: $569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,671.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,077.46 | 2019-2025 | |
| Abbvie INC. | $554.61 | 2019-2025 | |
| Lilly USA, LLC | $434.97 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $368.13 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $315.21 | 2019-2022 | |
| Astellas Pharma US INC | $289.25 | 2021-2025 | Veozah |
| Teva Pharmaceuticals USA, INC. | $282.38 | 2019-2021 | |
| Novo Nordisk INC | $268.98 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $251.03 | 2019-2021 | |
| Glaxosmithkline, LLC. | $218.86 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $208.68 | 2022-2025 | Repatha, Evenity, Prolia |
| Mylan Specialty L.P. | $169.73 | 2019-2023 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $159.77 | 2020-2025 | Rexulti, Nuedexta |
| Astrazeneca Pharmaceuticals LP | $153.18 | 2019-2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $129.79 | 2019-2024 | Xarelto |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.